Back
Compare AU
Compare CURE vs. DRIV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Betashares Electric Vehicles and Ftr Mobility ETF (DRIV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | DRIV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 85 | 72 |
Median incremental investment | $674.27 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,235.00 | $1,386.44 |
Average age group | > 35 | > 35 |
Key Summary
CURE | DRIV | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 47.62m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | DRIV.AX was created on 2021-12-13 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 15.85m in AUM and 48 holdings. DRIV.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to a portfolio of global companies at the forefront of innovation in automotive technology |
Top 3 holdings | Moderna Inc (2.64 %) Natera Inc (1.85 %) Twist Bioscience Corp (1.74 %) | SUMITOMO ELECTRIC INDUSTRIES L (8.68 %) VOLVO AB (8.15 %) TESLA INC (8.14 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (59.52 %) Consumer Discretionary (20.25 %) Industrials (11.65 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | United States (39.24 %) China (16.43 %) Germany (13.71 %) |
Management fee | 0.45 % | 0.67 % |
Key Summary
CURE | DRIV | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Solactive Future Mobility Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.67 % |
Price | $74.50 | $10.12 |
Size | $46.007 million | $15.608 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.03 % | 1.09 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 14/12/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | DRIV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 85 | 72 |
Median incremental investment | $674.27 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,235.00 | $1,386.44 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | DRIV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | DRIV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |